How Arcus Biosciences Aims To Take On Merck In Cancer Treatment Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug.
Why Is Arcus Biosciences Stock Trading Higher On Monday? Arcus Biosciences reports casdatifan monotherapy data in renal cancer, showing a 35% response rate and median progression-free survival not yet reached.
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus On CNBC's Mad Money Lightning Round, Jim Cramer endorsed buying Uranium Energy and called Arcus Biosciences a speculative play.
Gilead Lifts Annual Outlook As Yeztugo Launch Nears Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales.
Arcus Biosciences Shares Are Down Today: What's Going On? Arcus Biosciences Inc. (
NYSE: RCUS ) shares are trading lower Tuesday after the company announced a $150 million common stock offering.
RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q2 2024 RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
